TEAD1

HOUSTON--(BUSINESS WIRE)-- Sporos BioDiscovery, Inc. (a portfolio company of Sporos Bioventures, LLC.), a precision oncology company developing a diversified pipeline of small molecule therapeutic programs targeting cancer vulnerabilities in the tumor and tumor microenvironment, today announced that it will present two posters highlighting preclinical data from the company’s novel TEAD1 / TEAD4 isoform selective inhibitor, SPR1, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, CA. “We look forward to presenting two posters at this year’s AACR meeting that highlight the significant preclinical work we have done to characterize SPR1 as a potential best-in-class TEAD inhibitor. In addition, our team’s expert biological analysis has uncovered a new therapeutic vulnerability that could broaden the potential use of SPR1, a TEAD1/4 inhibitor, to a new subset of cancers with certain homozygous deletions,” said Stephen Rubino, Ph.D., President of Sporos BioDiscovery. Presentation Details: Title: TEAD1/4 inhibitors exhibit deeper biological impact and broader activity compared to TEAD1-only inhibitors in both monotherapy and combination without additional kidney toxicity Session Category: Experimental and Molecular Therapeutics Session Title: New Targets Session Date and Time: Tuesday Apr 9, 2024, 1:30 p.m. - 5:00 p.m. PT Abstract Number: 5913 Poster Number: 27 Title: VGLL4 is the target of the 3p25 homozygous deletion and presents a novel therapeutic vulnerability for TEAD1/4 but not TEAD1 inhibitors Session Category: Experimental and Molecular Therapeutics Session Title: YAP/TAZ/TEAD Modulators Session Date and Time: Wednesday Apr 10, 2024, 9:00 a.m. - 12:30 p.m. PT Abstract Number: 7266 Poster Number: 3 About Sporos BioDiscovery Sporos BioDiscovery, Inc. is a biotechnology research & development company with a diversified pipeline of several small molecule precision oncology therapeutic programs in development, including its lead candidate SPR1, a novel TEAD inhibitor program. Sporos BioDiscovery, Inc. is a portfolio company of Sporos Bioventures, LLC, a private biotechnology company focused on transforming the drug development process across oncology.

Pictured: A red illustration of a businessman walking through a door/iStock, lerbank Welcome to the first in a regular series of rundowns of people coming and going from the executive positions in the biopharma companies that BioSpace covers. This column will highlight the hired, fired, retired, promoted or resigning, and even those personally named in lawsuits. The big news of last week is that Richard Gonzalez will retire in July after 11 years as CEO of AbbVie, after helping AbbVie navigate the U.S. patent cliff for its blockbuster anti-inflammatory drug Humira. And just yesterday, we learned that ReNAgade Therapeutics, featured in this year’s NextGen list, is hiring its first-ever chief science innovation officer just under a year after the company’s launch. The fact that ReNAgade did not hire for this position sooner highlights a trend we’ve noticed in the industry toward leaner C-suites. It will be interesting to track whether this continues. Feb. 27 ReNAgade Therapeutics, which placed 6th in BioSpace’s 2024 NextGen class, hired former Moderna Therapeutics R&D boss Joe Bolen as its first chief science innovation officer. The company launched in May 2023 with the goal of building an integrated therapeutic platform that can provide all elements needed to produce RNA therapeutics. Feb. 27 Adaptimmune is bringing back Cintia Piccina as chief commercial officer, effective March 18. Piccina, who served in this role from January 2022 to March 2023, will lead the commercialization of afami-cel, an engineered TCR T cell therapy targeting solid tumors in advanced synovial sarcoma. The American-British firm has an Aug. 4 PDUFA date for afami-cel, formerly called ADP-A2M4CD8. Feb. 27 Vittoria Biotherapeutics has brought in Rosemary Mazanet to serve as chief medical officer. Mazanet will lead clinical development strategy and operations for the startup CAR T therapies developer, which recently received FDA clearance to initiate a Phase I clinical trial for its lead candidate, VIPER-101, a potential treatment for relapsed or refractory T cell lymphoma. Feb. 27 Domain Therapeutics has elevated Stephan Schann to the position of chief scientific officer. Formerly vice president of research, Schann will lead R&D and pipeline development for the multinational company, which is developing a pipeline of targeted cancer immunotherapies. Feb. 22 The Pharmaceutical Research and Manufacturers of America (PhRMA) tapped Gilead Sciences CEO Daniel O’Day to be its new board chair, succeeding Novartis CEO Vas Narasimhan. Pfizer CEO Albert Bourla and Sanofi CEO Paul Hudson will serve alongside O’Day, becoming PhRMA’s board chair-elect and treasurer. The industry powerhouse is navigating a rare string of setbacks in terms of membership and executive losses while it also puts up a united front against the Medicare Drug Price Negotiation Program under the Inflation Reduction Act. Feb. 22 Ocular Therapeutix announced several executive-level appointments, notably elevating Jeffrey Heier from director and advisor to chief scientific officer. The news coincided with Ocular securing a $325 million private placement, which the company will apply to development of Axpaxli (axitinib intravitreal implant) for treatment of wet age-related macular degeneration. Feb. 21 AbbVie announced that CEO Richard Gonzalez will retire July 1. He will be succeeded by current President and COO Robert Michael. Gonzalez, who has helmed AbbVie since its 2013 spinoff from Abbott Laboratories, will become executive chairman. Gonzalez’s departure comes as AbbVie has been active in the M&A space, including its $10 billion buy of ImmunoGen in November 2023 and the $8.7 billion deal for Cerevel Therapeutics in December 2023. In an SEC filing this month, Cerevel reported that the company and AbbVie were handed a request for additional information and documentary materials (second request) from the Federal Trade Commission regarding the regulator’s review of the merger. Gonzalez also helped AbbVie navigate the U.S. patent cliff for its blockbuster anti-inflammatory drug Humira, helping the company to successfully withstand competition from low-cost biosimilars. Gonzalez said in AbbVie’s fourth quarter and full-year 2023 investor call that there was a connection between Humira’s loss of exclusivity (LOE) and his future with the company. “When we believe that we are comfortable, we’ve navigated the LOE, and the rest of the business is performing at high level, that’s the point at which we want to make the transition,” he said. Feb. 21 Narcan (naloxone) maker Emergent BioSolutions brought in Joseph Papa as president and CEO, replacing interim CEO Haywood Miller. Papa, former CEO of Bausch + Lomb, Valeant Pharmaceuticals and Perrigo, is reportedly tasked with engineering a turnaround, as he did at Bausch. Feb. 21 Saghmos Therapeutics named former FDA official Stephen Grant chief regulatory officer. The company is turning to Grant, former deputy director of the FDA Division of Cardiology and Nephrology, to help shepherd compounds including cardiorenal metabolic modulator ST-62516 (trimetazidine) through the review and approval process. Saghmos recently announced a notice of allowance for a U.S. patent on the drug, which seeks to reduce acute kidney injury and major adverse cardiac and kidney events during contrast procedures in patients with chronic kidney disease. Feb. 21 Sergio Santillana resigned as CMO of Ikena Oncology and was replaced by Caroline Germa, the company said. Ikena is currently in early-stage clinical trials with two candidate targeted cancer therapies, the IK-930 TEAD1 selective hippo pathway inhibitor and the IK-595 MEK-RAF “molecular glue.” Feb. 21 Synthekine announced several C-suite changes, including the promotion of Martin Oft to chief scientific officer and the hiring of Geoff Nosrati as chief business officer. The cytokine therapeutics startup is in a Phase I clinical trial with an orthogonal IL-2 and CD19 CAR-T combination therapy currently called STK-009 + SYNCAR-001. Last month, Synthekine formed a partnership with Sanofi US to develop and market IL-10 receptor agonists for inflammatory conditions. Feb. 21 James Burke left CG Oncology to become CMO at KaliVir Immunotherapeutics. Pittsburgh-based KaliVir recently obtained FDA IND clearance for a Phase I clinical study of ASP1012, a systemic oncolytic vaccinia virus therapy licensed to Astellas Pharma. The trial includes subjects with locally advanced or metastatic solid tumors. Feb. 20 Phil Pang, executive vice president and CMO of Vir Biotechnology, will step down at the end of March, the company said. Just last week, Vir reported that GSK decided to terminate a partnership to research, develop and commercialize Vir’s monoclonal antibodies for the prevention, treatment or prophylaxis of the influenza virus. Vir now will hold sole rights to its investigational flu therapies. Neil Versel is the business editor at BioSpace. You can reach him at neil.versel@biospace.com. Follow him on LinkedIn or X.

STOCKHOLM, Feb. 14, 2024 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for Cancer Research's Annual Meeting 2024. The conference will take place on April 5-10, 2024 in San Diego, California. Dr Peter Brandt, Head of Chemistry, will present a poster entitled Degraders of TEAD transcription factors based on interface 3 binders on Sunday April 7, 2024, at 1:30 PM – 5:00 PM. The location is at the San Diego Convention Center, Section 52, abstract presentation number: LB029. The session title is Late-Breaking Research: Chemistry. The presentation will include new positive results from studies with novel proteolysis-targeting degraders of TEAD based on interface 3-binding ligands under development by Beactica. This will include head-to-head in vitro comparisons with other classes of TEAD modulators in clinical development such as palmitoylation inhibitors and direct YAP–TEAD protein–protein interaction inhibitors. The work to be presented contains contributions by Beactica's collaborators at the National Center for Advancing Translational Sciences (NCATS), one of 27 institutes and centers at the U.S. National Institutes of Health (NIH). Organised by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world. It has an anticipated attendance of more than 20 000 scientists, clinicians, advocates, and other attendees. The event spans integrative cancer science, global impact, individualised patient care and showcases the best and most up-to-date cancer science available. About TEAD TEAD 1–4 (Transcriptional Enhanced Associate Domain) are transcription factors that together with its coactivators YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif) play key roles in the Hippo signalling pathway that regulates cell proliferation, apoptosis, and stemness. Dysregulation of the Hippo pathway and subsequent activation of TEAD has been reported in a wide range of cancers such as squamous cell carcinoma, head and neck, gynaecological, and gastrointestinal cancers. The first clinical proof-of-concept for drugging the Hippo–YAP–TEAD pathway was achieved with the TEAD inhibitor VT3989 and was presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2023. About Beactica Therapeutics Beactica Therapeutics AB is a privately held precision oncology company committed to the fight against cancer. The company is advancing a pipeline of novel small molecule therapeutics with a focus to treat genetically defined cancers with significant unmet medical need. Beactica's approach is centered around targeting synthetically lethal disease proteins with allosteric modulators and targeted protein degraders. Beactica deliver value to patients and shareholders by advancing its programmes to clinical proof of concept. For more information, please visit . Beactica Therapeutics Contact Per Källblad M.Sc. Ph.D. CEO [email protected] Tel: +46 18 56 08 80 The following files are available for download: SOURCE Beactica Therapeutics AB